Sign up Australia
Proactive Investors - Run By Investors For Investors

Paradigm's Paul Rennie discusses momentum of the Ross River Virus Clinical Trial

The clinical trial is of the drug Pentosan Polysulfate Sodium for the treatment of Ross River virus.
Paradigm's Paul Rennie discusses momentum of the Ross River Virus Clinical Trial
Desc: Paul Rennie, chief executive officer, Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd (ASX:PAR) continues to advance its Phase 2 Ross River Virus Clinical Trial, with 25% of the 24-participant total having now been dosed across the initial two trial sites in Geelong and Brisbane.

This follows the commencement of the trial in August 2017.

A third trial site has been initiated in Echuca, and a fourth on the Gold Coast.

Trial participants will be evaluated for safety, tolerability and effects on disease symptoms, with results anticipated in Q2 CY2018.

Paul Rennie, chief executive officer, commented:

"We are very pleased to have such strong momentum in this trial so far, with a quarter of the 24-participant total now dosed following the trial’s commencement just last month.

"This strong start in recruiting eligible patients follows the outbreak of RRv seen earlier in 2017.

"Given RRv outbreaks are seasonal, we need to add more sites to keep our recruitment rates as high as possible.

"We look forward to initiating our fourth trial site in the Gold Coast over the coming weeks and recruiting more participants over the coming months.

"Ross River virus is a disease with a significant unmet medical need and we hope that PPS can prove to be an effective treatment.

"Current therapeutics can help to manage the joint pain associated with the virus but they have not been shown to treat the detrimental effects on joint cartilage that are associated with the disease.

"Current treatment options are also often inadequate in providing symptom relief, or associated with significant gastrointestinal side effects in patients with symptoms of joint pain which persist beyond the acute phase."

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

The Hydroponics Company Ltd issued a cannabis research licence
July 11 2017
The licence allows Canndeo to build its exclusive Plant Breeders Rights.
May 31 2017
Written responses from America’s Food & Drug Administration and the Medicines & Healthcare products Regulatory Agency (MHRA) here in Britain support its timeline, which sees marketing approval for the product in the second-quarter of 2019.
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use